These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 25586125

  • 1. MiRNA‑542‑3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation.
    Ma T, Yang L, Zhang J.
    Oncol Rep; 2015 Mar; 33(3):1215-20. PubMed ID: 25586125
    [Abstract] [Full Text] [Related]

  • 2. FOXO1A is a target for HER2-overexpressing breast tumors.
    Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV.
    Cancer Res; 2010 Jul 01; 70(13):5475-85. PubMed ID: 20551062
    [Abstract] [Full Text] [Related]

  • 3. miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation.
    Wuerkenbieke D, Wang J, Li Y, Ma C.
    Arch Gynecol Obstet; 2015 Nov 01; 292(5):1109-16. PubMed ID: 25986891
    [Abstract] [Full Text] [Related]

  • 4. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C, Duan X, Xu L, Ye J, Zhao J, Liu Y.
    Breast Cancer Res Treat; 2012 Dec 01; 136(3):739-48. PubMed ID: 23117856
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
    Fleming IN, Andriu A, Smith TA.
    Breast Cancer Res Treat; 2014 Apr 01; 144(2):241-8. PubMed ID: 24522376
    [Abstract] [Full Text] [Related]

  • 7. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H.
    Ann Oncol; 2010 Feb 01; 21(2):255-262. PubMed ID: 19633047
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT, Metz MZ, Kane SE.
    Breast Cancer Res Treat; 2005 May 01; 91(2):187-201. PubMed ID: 15868447
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A, Colomer R, Brunet J, Menendez JA.
    Int J Oncol; 2007 Oct 01; 31(4):769-76. PubMed ID: 17786307
    [Abstract] [Full Text] [Related]

  • 11. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
    Ye XM, Zhu HY, Bai WD, Wang T, Wang L, Chen Y, Yang AG, Jia LT.
    BMC Cancer; 2014 Feb 26; 14():134. PubMed ID: 24571711
    [Abstract] [Full Text] [Related]

  • 12. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.
    Mol Pharmacol; 2006 Nov 26; 70(5):1534-41. PubMed ID: 16887935
    [Abstract] [Full Text] [Related]

  • 13. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
    Zheng L, Ren JQ, Chen Q, Zhang HP, Zhu HG.
    Zhonghua Zhong Liu Za Zhi; 2004 Oct 26; 26(10):594-7. PubMed ID: 15634518
    [Abstract] [Full Text] [Related]

  • 14. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
    Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D.
    Cancer Cell; 2004 Aug 26; 6(2):117-27. PubMed ID: 15324695
    [Abstract] [Full Text] [Related]

  • 15. Sensitization of breast cancer cells to radiation by trastuzumab.
    Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z.
    Mol Cancer Ther; 2003 Nov 26; 2(11):1113-20. PubMed ID: 14617784
    [Abstract] [Full Text] [Related]

  • 16. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
    Zhao Y, Wang Z, Jiang Y, Yang C.
    Cancer Lett; 2011 Dec 26; 313(1):54-63. PubMed ID: 21943825
    [Abstract] [Full Text] [Related]

  • 17. Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance.
    Liu D, Shi M, Duan C, Chen H, Hu Y, Yang Z, Duan H, Guo N.
    Mol Immunol; 2013 Nov 26; 56(1-2):104-12. PubMed ID: 23711387
    [Abstract] [Full Text] [Related]

  • 18. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
    Clark AS, West K, Streicher S, Dennis PA.
    Mol Cancer Ther; 2002 Jul 26; 1(9):707-17. PubMed ID: 12479367
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.